[go: up one dir, main page]

AR058703A1 - Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer - Google Patents

Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer

Info

Publication number
AR058703A1
AR058703A1 ARP060105671A ARP060105671A AR058703A1 AR 058703 A1 AR058703 A1 AR 058703A1 AR P060105671 A ARP060105671 A AR P060105671A AR P060105671 A ARP060105671 A AR P060105671A AR 058703 A1 AR058703 A1 AR 058703A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
phenyl
cycloalkyl
optionally substituted
Prior art date
Application number
ARP060105671A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058703(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR058703A1 publication Critical patent/AR058703A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1) y N-oxidos, profármacos, sales aceptables para uso farmacéutico, solvatos y sus isomeros estereoquímicos, donde: R1 es heteroarilo mono o bicíclico, o piridin-2-on-ilo, donde dicho heteroarilo está sustituido opcionalmente con uno, dos o tres sustituyentes Ra; donde Ra es NH2, halogeno, alcoxi, alquiléter, alquiltio, alquilsulfonilo, fenilsulfonilo, heteroarilsulfonilo, heterociclilsulfonilo, -SO2NH2, alquilsulfonamida, alquilo, aminoalquilo, alquilamino, fenilo, heteroarilo, ciano, alquenilo, alquinilo, cicloalquilo, heterociclilo, -CO2-alquilo, -C(O)-Rb, -alquil C(1-4)-morfolinilo, -alquil C(1-4)-piperidinilo, -alquil C(1-4)-piperazinilo, -alquil C(1-4)-N'-metil piperazinilo, -alquil C(1-4)-Rb, -C(O)NH-alquil C1-4)-Rb, o -C(O)NRcRd; donde Rb es heterociclilo, alquilsulfonilo, -SO2NH2, alquilsulfonamida, -OH, -Oalquilo, -NH2-, -NHalquilo, o -N(alquilo)2; Rc y Rd se seleccionan independientemente de: H, fenilo, heteroarilo, o alquilo C1-6, donde dicho alquilo C1-6 puede estar sustituido opcionalmente con un sustituyente seleccionado de: -N(CH3)2, morfolinilo, piperidinilo, piperazinilo, N-metil piperazinilo, alquilsulfonilo, -SO2NH2, alquilsulfonamida, hidroxilo y alcoxi; o Rc y Rd juntos pueden formar un anillo heterocíclico de 5 a 7 miembros, que opcionalmente contiene un segundo resto heteroatomico seleccionado de O, NH, N(alquilo), SO, SO2, o S; donde dicho anillo heterocíclico Rc-Rd está sustituído opcionalmente con alquilo, -SO2alquilo, o -C(O)alquilo; A es un anillo seleccionado del grupo que consiste en: fenilo, heteroarilo mono o bicíclico, 3-(4-metoxi-bencil)-3H-quinazolin-4-on-6-ilo, quinazolin-4-on-6-ilo, y heterociclilo benzo- fusionado; donde dicho fenilo, heteroarilo o heterociclilo benzo-fusionado están sustitiudos opcionalmente con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en: -OH, alquilo, fenilo, heteroarilo, alcoxi, -CN, halogeno, nitro, -NH2, -N(CH3)2, -NHc(O) NHalquilo C1-6, y -NHC(O)alquilo C1-6; R5 y R6 se seleccionan independientemente de: H, F, alquilo C1-6, -OH, -Oalquilo C1-6, -NHalquilo C1-6 o -N(alquilo C1-6)2; o R5 y R6 pueden formar juntos un anillo cicloalquilo C3-5, un grupo aziridinilo o un grupo epoxidilo; y R7 y R8 son H, halogeno o alquilo C1-6.
ARP060105671A 2005-12-21 2006-12-20 Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer AR058703A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75263405P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
AR058703A1 true AR058703A1 (es) 2008-02-20

Family

ID=37964498

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105671A AR058703A1 (es) 2005-12-21 2006-12-20 Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer

Country Status (40)

Country Link
US (2) US8030305B2 (es)
EP (1) EP1966214B9 (es)
JP (1) JP5292102B2 (es)
KR (1) KR101412675B1 (es)
CN (1) CN101374843B (es)
AP (1) AP3433A (es)
AR (1) AR058703A1 (es)
AU (1) AU2006331912B2 (es)
BR (1) BRPI0620292B1 (es)
CA (1) CA2634721C (es)
CR (1) CR10170A (es)
CY (1) CY1118846T1 (es)
DK (1) DK1966214T3 (es)
EA (1) EA015754B1 (es)
EC (1) ECSP088573A (es)
ES (1) ES2612377T3 (es)
GT (1) GT200800105A (es)
HN (1) HN2008000931A (es)
HR (1) HRP20170103T1 (es)
HU (1) HUE030390T2 (es)
IL (1) IL192108A (es)
LT (1) LT1966214T (es)
MA (1) MA30084B1 (es)
ME (1) ME02736B (es)
MX (1) MX2008008277A (es)
MY (1) MY159523A (es)
NI (1) NI200800179A (es)
NO (1) NO340958B1 (es)
NZ (1) NZ568807A (es)
PE (2) PE20070752A1 (es)
PL (1) PL1966214T3 (es)
PT (1) PT1966214T (es)
RS (1) RS55630B1 (es)
SV (1) SV2008002963A (es)
TN (1) TNSN08278A1 (es)
TW (1) TWI399378B (es)
UA (1) UA98297C2 (es)
UY (1) UY30041A1 (es)
WO (1) WO2007075567A1 (es)
ZA (1) ZA200806277B (es)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588180A1 (en) * 2004-12-17 2006-06-22 Bionovo, Inc. Method of using extracts of epimedium species
US7482029B2 (en) * 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
US7700136B2 (en) * 2005-11-14 2010-04-20 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
IN2014KN02423A (es) 2006-04-07 2015-05-01 Vertex Pharma
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
CA2660836A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
JP2010507577A (ja) * 2006-10-23 2010-03-11 エスジーエックス ファーマシューティカルズ、インコーポレイテッド トリアゾロピリダジンタンパク質キナーゼモジュレーター
EP2407783A1 (en) 2006-10-27 2012-01-18 Janssen Pharmaceutica, N.V. A method for pharmacologically profiling compounds
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
DK2497470T3 (en) 2006-11-22 2015-12-07 Incyte Holdings Corp Imidazotriaziner and imidazopyrimidines as kinase inhibitors
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
US8629144B2 (en) 2007-06-21 2014-01-14 Janssen Pharmaceutica Nv Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
US20090042818A1 (en) * 2007-06-22 2009-02-12 Bionovo, Inc. Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists
US20080319051A1 (en) * 2007-06-22 2008-12-25 Bionovo, Inc. Liquiritigenin and derivatives as selective estrogen receptor beta agonists
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
AU2008285325A1 (en) * 2007-08-08 2009-02-12 Bionovo, Inc. Extracts of Ligustrum lucidum and uses thereof
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
FR2929613B1 (fr) * 2008-04-02 2010-12-31 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
FR2919870B1 (fr) * 2007-08-09 2014-05-16 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
DE102007038957A1 (de) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
CA2698719A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of asparagus conchinchinensis (lour.) merr of the liliaceae family and uses thereof
JP2010539086A (ja) * 2007-09-07 2010-12-16 バイオノボ・インコーポレーテッド マメ科ファミリーのクズのエストロゲン性抽出物およびその使用
JP2010539085A (ja) * 2007-09-07 2010-12-16 バイオノボ・インコーポレーテッド マメ科ファミリーのキバナオウギのエストロゲン性抽出物およびその使用
US9155770B2 (en) * 2007-09-07 2015-10-13 Bionovo, Inc. Estrogenic extracts of Scuttelaria barbata D. don of the labiatae family and uses thereof
EP2222321A4 (en) * 2007-11-19 2013-02-13 Bionovo Inc THERAPY AGAINST CANCER WITH AN EXTRACT OF SCUTELLARIA BARBATA
WO2009067555A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Scutellaria barbata extract and combinations for the treatment of cancer
EP2219659A4 (en) * 2007-11-19 2010-11-17 Bionovo Inc METHODS OF DETECTION AND TREATMENT OF CANCERS USING BARBATA SCUTTELARIA EXTRACT
US8197868B2 (en) * 2007-11-19 2012-06-12 Bionovo, Inc. Process of making purified extract of Scutellaria barbata D. Don
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
MY152685A (en) * 2008-02-05 2014-10-31 Sanofi Aventis Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
BRPI0907487A2 (pt) 2008-02-05 2015-07-14 Sanofi Aventis Sais de triazólio como inibidores de par1, produção dos mesmos e uso como medicamentos
AU2009211887B2 (en) * 2008-02-05 2013-09-19 Sanofi Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments
CA2717034A1 (en) 2008-02-28 2009-09-03 Pascal Furet Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
CA2721191A1 (en) * 2008-04-14 2009-10-22 Bionovo, Inc. Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
US20090304825A1 (en) * 2008-05-06 2009-12-10 Bionovo, Inc. Estrogenic extracts for use in treating vaginal and vulvar atrophy
CN103936743B (zh) 2008-05-21 2018-04-24 因西特控股公司 2-氟-N-甲基-4-[7-(喹啉-6-基甲基)咪唑并[1,2-b][1,2,4]三嗪-2-基]苯甲酰胺的盐及与其相关的制备方法
AU2009256028A1 (en) * 2008-06-05 2009-12-10 Bionovo, Inc. Method of quantification of multiple bioactives from botanical compositons
AU2009255626A1 (en) * 2008-06-06 2009-12-10 Bionovo, Inc. Anthraquinones and analogs from Rhuem palmatum for treatment of estrogen receptor beta-mediated conditions
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
FR2941229B1 (fr) * 2009-01-21 2012-11-30 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
EA201170222A1 (ru) * 2008-07-18 2011-08-30 Санофи-Авентис НОВЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛО[4,3-a]ПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И НОВОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ МЕТ
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
US20100069481A1 (en) * 2008-09-03 2010-03-18 Bionovo, Inc. Methods and compositions for the treatment of cancer
JP2012509342A (ja) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
WO2010072295A1 (en) 2008-12-22 2010-07-01 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
EP2406264A4 (en) 2009-03-09 2012-08-08 Univ California SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINE AND GABAA RECEPTORS
WO2010129343A2 (en) * 2009-04-28 2010-11-11 Bionovo, Inc. Method of reducing fat accumulation and inducing weight loss
US8389526B2 (en) * 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
CN102548995B (zh) * 2009-08-12 2015-01-28 诺华股份有限公司 杂环腙化合物以及它们治疗癌症和炎症的用途
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
DE102009056886A1 (de) * 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
WO2011079804A1 (en) 2009-12-31 2011-07-07 Hutchison Medipharma Limited Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
AU2011269788B2 (en) 2010-02-03 2015-12-10 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-Met inhibitors
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105130948A (zh) * 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP2593462B1 (en) * 2010-07-14 2016-09-07 Betta Pharmaceuticals Co., Ltd. Novel fused heterocyclic derivatives useful as c-met tyrosine kinase inhibitors
ES2603032T3 (es) 2010-07-15 2017-02-23 Bayer Intellectual Property Gmbh Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102532141A (zh) * 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
CN102516263B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
KR20130091464A (ko) * 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
KR101869534B1 (ko) * 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
WO2013151913A1 (en) 2012-04-03 2013-10-10 Novartis Ag Tyrosine kinase inhibitor combinations and their use
RU2660354C2 (ru) 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
ES2904321T3 (es) * 2012-07-27 2022-04-04 Sato Pharma Procedimiento para preparar compuestos de difluorometileno
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
CN104250257B (zh) * 2013-06-25 2017-06-16 上海翰森生物医药科技有限公司 3,4‑二氢‑1H‑苯并[c][1,2]噁硼酸类化合物或其可药用盐及其制备方法和用途
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
SI3122359T1 (sl) 2014-03-26 2021-05-31 Astex Therapeutics Ltd. Kombinacije inhibitorja FGFR in inhibitorja IGF1R
CA2943682C (en) * 2014-03-26 2024-02-13 Astex Therapeutics Ltd Combinations of fgfr and cmet inhibitors and their use for the treatmentof cancer
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
EP3424534B1 (en) 2014-04-15 2021-06-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
TWI695837B (zh) 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
BR112017010232A2 (pt) * 2014-12-11 2018-01-02 Merck Patent Gmbh Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um derivado de quinazolina
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN106279176B (zh) * 2015-06-11 2020-09-08 中国科学院上海药物研究所 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用
MX2017016875A (es) 2015-06-26 2018-04-24 Takeda Pharmaceuticals Co Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico colinergico m1.
HRP20201157T1 (hr) 2015-09-23 2020-11-13 Janssen Pharmaceutica N.V. Triciklički heterocikli za liječenje raka
LT3353164T (lt) 2015-09-23 2022-01-25 Janssen Pharmaceutica, N.V. Diheteroarilpakeistieji 1,4-benzodiazepinai ir jų naudojimas vėžio gydymui
US10301325B2 (en) 2015-09-24 2019-05-28 Shanghai Haiju Biological Technology Co., Ltd. Quinoline derivative, and pharmaceutical composition, preparation method and use thereof
US10548899B2 (en) 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
CN106924260B (zh) * 2015-12-31 2018-05-25 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
CN109819653A (zh) * 2016-08-16 2019-05-28 拜耳作物科学股份公司 制备2-(3,6-二卤代吡啶-2-基)-3H-咪唑[4,5-c]吡啶衍生物的方法以及通过3H-咪唑[4,5-c]吡啶衍生物与有机金属锌胺碱的反应得到的相关化合物
CA3045121A1 (en) * 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
TWI774755B (zh) * 2017-04-28 2022-08-21 日商佐藤製藥股份有限公司 二氟甲烯化合物之製造法
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. COMPOUNDS AND THEIR METHODS OF USE
WO2019201718A1 (en) * 2018-04-18 2019-10-24 Basf Se D-glucaro-6,3-lactone monoester and a process for the preparation thereof
KR102809796B1 (ko) 2018-05-30 2025-05-20 프락시스 프리시젼 메디신즈, 인크. 이온 채널 조절인자
CN109045036B (zh) * 2018-07-19 2020-10-02 中山大学 [1,2,4]三唑并[4,3-b]哒嗪衍生物在制备抗肿瘤药物中的应用
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
EP3893872B1 (en) 2018-12-14 2024-07-17 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof
US12180207B2 (en) 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
CN110156805B (zh) * 2019-05-22 2020-12-11 南京合巨药业有限公司 一种2, 3-二氢-1, 4-二氧代[2,3-b]吡啶-7-羧酸的制备方法
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
WO2021222045A1 (en) * 2020-04-26 2021-11-04 Apollomics Inc. Novel pharmaceutical formulation for c-met inhibitor
TWI728882B (zh) 2020-07-28 2021-05-21 祥昇機電工業有限公司 自吸式抽水機之釋氣機構
WO2024032647A1 (zh) * 2022-08-09 2024-02-15 上海济煜医药科技有限公司 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
WO2025007275A1 (zh) * 2023-07-04 2025-01-09 北京浦润奥生物科技有限责任公司 [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US181455A (en) * 1876-08-22 Improvement in brooms
US16625A (en) * 1857-02-10 Arraitg-ement of springs for vehicles
US147568A (en) * 1874-02-17 Improvement in paper-folding attachments for printing-presses
US192696A (en) * 1877-07-03 Improvement in combined cut-off and filter
US111495A (en) * 1871-01-31 Stinb
US96322A (en) * 1869-11-02 Improvement in combined cultivator and seed-planter
US17309A (en) * 1857-05-12 Portable gas co
US261297A (en) * 1882-07-18 Mortar for stamp-mills
US171798A (en) * 1876-01-04 Improvement in spring attachments for cradles
US138264A (en) * 1873-04-29 Improvement in machines for cutting out planchets of sheet metal
NL128591C (es) 1965-07-02
US3506656A (en) 1966-10-22 1970-04-14 Boehringer Mannheim Gmbh Triazolo-tetrazolo-pyridazine derivatives
NL130097C (es) 1966-10-22
DE2222834A1 (de) 1972-05-10 1973-11-29 Boehringer Mannheim Gmbh Nitrofuryl-amidin-derivate und verfahren zur herstellung derselben
DE2030581A1 (de) 1970-06-20 1971-12-30 Boehringer Mannheim GmbH, 6800 Mannheim-Waldhof Nitrofuryl-amidin-Derivate und Verfahren zur Herstellung derselben
US3823137A (en) 1970-06-20 1974-07-09 Boehringer Mannheim Gmbh Novel nitrofuran compounds and pharmaceutical compositions
DE2161587A1 (de) 1971-12-11 1973-06-14 Boehringer Mannheim Gmbh Nitrofuryl-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazinderivat
DE2113438A1 (de) 1971-03-19 1972-09-21 Boehringer Mannheim Gmbh Nitrofuryl-triazolo[4,3-b]pyridazinderivate
GB1324060A (en) 1971-03-19 1973-07-18 Boehringer Mannheim Gmbh Nitrofuryl-triazolo 4,3-b pyridazine derivatives
DE2147013A1 (de) 1971-09-21 1973-03-29 Boehringer Mannheim Gmbh Antimikrobiell wirksame nitrofuranderivate und verfahren zur herstellung derselben
JPS5612390A (en) * 1979-07-10 1981-02-06 Yoshitomi Pharmaceut Ind Ltd Triazolopyridazine derivative
US4260755A (en) 1979-10-31 1981-04-07 American Cyanamid Company Novel 6-phenyl and substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines
FR2562071B1 (fr) 1984-03-30 1986-12-19 Sanofi Sa Triazolo(4,3-b)pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja) 1987-06-12 1988-12-19 Yoshitomi Pharmaceut Ind Ltd 縮合ピリダジン化合物
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
CA2044564A1 (en) 1990-06-28 1991-12-29 Quirico Branca Amino acid derivatives
US5278161A (en) 1990-06-28 1994-01-11 Hoffmann-La Roche Inc. Amino acid derivatives useful as renin inhibitors
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
DE4309285A1 (de) 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
JPH06331089A (ja) 1993-05-18 1994-11-29 Asahi Organic Chem Ind Co Ltd プラスチック管の電気溶着方法
TW304878B (es) 1993-09-21 1997-05-11 Takeda Pharm Industry Co Ltd
KR19990007865A (ko) 1995-04-19 1999-01-25 스피겔알렌제이 약물 방출용 피복 스텐트
US20020111495A1 (en) 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US6297235B1 (en) 1997-08-28 2001-10-02 Merck Sharp & Dohme Ltd. Triazolopyridazine derivatives for treating anxiety and enhancing cognition
GB9718254D0 (en) 1997-08-28 1997-11-05 Merck Sharp & Dohme Therapeutic agents
GEP20032868B (en) * 1998-01-21 2003-01-27 Merck Sharp & Dohme Triazolo-Pyridazine Derivatives as Ligands for Gaba Receptors, Methods for Their Production, Pharmaceutical Compositions Containing the Same for Treatment and/or Prevention of disorders of Central Nervous System
GB9801208D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
GB9816654D0 (en) 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
ATE269357T1 (de) 1999-04-28 2004-07-15 Univ Texas Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf
WO2001034603A2 (en) 1999-11-12 2001-05-17 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
DE60203652T2 (de) 2001-01-31 2005-09-08 Pfizer Products Inc., Groton Nikotinsäureamid-Derivate und ihre Mimetika als Inhibitoren von PDE4-Isozyme
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
DE60220779T2 (de) 2001-04-20 2008-03-06 Sanofi-Aventis Tetrahydropyridyl-alkyl-heterozykle, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten
US20050065118A1 (en) 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
CN1281606C (zh) 2002-03-01 2006-10-25 安斯泰来制药有限公司 含氮杂环化合物
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6793457B2 (en) * 2002-11-15 2004-09-21 General Electric Company Fabricated repair of cast nozzle
US7268136B2 (en) 2002-12-18 2007-09-11 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
CA2529558A1 (en) 2003-07-01 2005-01-13 Astellas Pharma Inc. Agent inducing increase in bone mass
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
WO2005004607A1 (en) * 2003-07-02 2005-01-20 Sugen, Inc. Arylmethyl triazolo and imidazopyrazines as c-met inhibitors
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7728017B2 (en) * 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
EP2032578A2 (en) 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso

Also Published As

Publication number Publication date
UY30041A1 (es) 2007-05-31
AP2008004502A0 (en) 2008-06-30
RS55630B1 (sr) 2017-06-30
WO2007075567A1 (en) 2007-07-05
JP2009525263A (ja) 2009-07-09
US8173654B2 (en) 2012-05-08
CN101374843A (zh) 2009-02-25
EA015754B1 (ru) 2011-12-30
IL192108A (en) 2014-02-27
ME02736B (me) 2017-10-20
NO340958B1 (no) 2017-07-31
MY159523A (en) 2017-01-13
EP1966214B9 (en) 2017-09-13
MA30084B1 (fr) 2008-12-01
CR10170A (es) 2008-11-24
US20070203136A1 (en) 2007-08-30
PT1966214T (pt) 2017-02-03
IL192108A0 (en) 2008-12-29
BRPI0620292B1 (pt) 2021-08-24
AU2006331912B2 (en) 2012-08-30
LT1966214T (lt) 2017-02-10
KR20080085154A (ko) 2008-09-23
BRPI0620292A2 (pt) 2011-11-08
NZ568807A (en) 2011-05-27
KR101412675B1 (ko) 2014-07-03
PE20070752A1 (es) 2007-08-13
ZA200806277B (en) 2010-09-29
DK1966214T3 (en) 2017-02-13
CA2634721C (en) 2014-06-17
EP1966214B1 (en) 2016-11-02
UA98297C2 (en) 2012-05-10
ECSP088573A (es) 2008-07-30
HRP20170103T1 (hr) 2017-03-24
ES2612377T3 (es) 2017-05-16
PL1966214T3 (pl) 2017-04-28
PE20110008A1 (es) 2011-01-31
MX2008008277A (es) 2009-03-04
AP3433A (en) 2015-10-31
US20090098181A1 (en) 2009-04-16
JP5292102B2 (ja) 2013-09-18
HUE030390T2 (en) 2017-05-29
TW200801007A (en) 2008-01-01
NI200800179A (es) 2016-01-06
SV2008002963A (es) 2010-01-18
AU2006331912A1 (en) 2007-07-05
CN101374843B (zh) 2012-09-05
HN2008000931A (es) 2013-10-22
NO20083013L (no) 2008-09-19
CY1118846T1 (el) 2018-01-10
GT200800105A (es) 2008-10-10
US8030305B2 (en) 2011-10-04
CA2634721A1 (en) 2007-07-05
EP1966214A1 (en) 2008-09-10
TWI399378B (zh) 2013-06-21
EA200870085A1 (ru) 2008-12-30
TNSN08278A1 (en) 2009-10-30

Similar Documents

Publication Publication Date Title
AR058703A1 (es) Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer
UY28526A1 (es) Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
RU2018121499A (ru) Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1
AR048315A1 (es) Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas.
AR078786A1 (es) Derivados de la cromenona
PE20080841A1 (es) Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion
AR035626A1 (es) Compuestos de indol inhibidores de tirosina quinasa, composicion farmaceutica, procedimiento para prepararla,y, uso de los compuestos en la preparación de medicamentos
AR069417A1 (es) Piperidinas heteroaril - sustituidas
UY28578A1 (es) Derivados de amida
UY29177A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR051997A1 (es) Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos
HRP20171999T1 (hr) Novi derivati aminopirimidina
AR048346A1 (es) Piridonas sustituidas como inhibidores de poli(adp-ribosa)-polimerasa (parp), composiciones farmaceuticas que las contienen y el uso de las mismas para el tratamiento de trastornos cardiovasculares y del sistema nervioso central.
AR066659A1 (es) Derivados de espiroindolinona
AR087355A1 (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
AR062503A1 (es) Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor.
AR058401A1 (es) Pirimidinas sustituidas con sulfoximinas proceso para su produccion y uso de las mismas como farmacos
AR054320A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
AR039648A1 (es) Compuestos de aril cetona pirrolo triazina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee